1. Home
  2. NOAH vs RGNX Comparison

NOAH vs RGNX Comparison

Compare NOAH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

HOLD

Current Price

$10.31

Market Cap

653.4M

Sector

Finance

ML Signal

HOLD

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$8.87

Market Cap

528.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOAH
RGNX
Founded
2005
2008
Country
China
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.4M
528.6M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
NOAH
RGNX
Price
$10.31
$8.87
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$11.00
$28.75
AVG Volume (30 Days)
71.2K
1.5M
Earning Date
05-27-2026
05-05-2026
Dividend Yield
5.66%
N/A
EPS Growth
N/A
18.08
EPS
N/A
N/A
Revenue
N/A
$10,393,000.00
Revenue This Year
N/A
$51.21
Revenue Next Year
$5.71
$19.08
P/E Ratio
$13.29
N/A
Revenue Growth
N/A
126.48
52 Week Low
$9.53
$5.46
52 Week High
$12.84
$16.19

Technical Indicators

Market Signals
Indicator
NOAH
RGNX
Relative Strength Index (RSI) 44.73 64.17
Support Level $9.83 $8.68
Resistance Level $10.77 $9.67
Average True Range (ATR) 0.27 0.63
MACD -0.00 0.31
Stochastic Oscillator 35.71 87.96

Price Performance

Historical Comparison
NOAH
RGNX

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Share on Social Networks: